Article Text

Download PDFPDF

621 A Tregs depleting, CD25-targeted antibody-drug conjugate synergizes with tumor-targeted radiotherapy and systemic interleukin-2 in pre-clinical models of solid cancers
  1. Patrick van Berkel and
  2. Francesca Zammarchi
  1. ADC Therapeutics, London, UK


Background Regulatory T cells (Tregs) contribute to an immunosuppressive tumor microenvironment. High tumor infiltration by Tregs and a low ratio of Teffector cells/Tregs is often associated with poor prognosis in solid tumors.1 Tregs represent a major obstacle to cancer immunotherapies, including checkpoint inhibitors and interleukin-2 (IL-2) and are associated with tumors resistance to radiotherapy.2 CD25-ADC (a.k.a. sur301) is an antibody-drug conjugate (ADC) composed of rat monoclonal antibody PC61, directed against mouse CD25, conjugated to tesirine, a pyrrolobenzodiazepine (PBD) dimer-based protease-cleavable linker.3 Previously we showed that single low doses of CD25-ADC resulted in potent and durable antitumor activity in established syngeneic solid tumor models and the combination of a suboptimal dose was synergistic with PD-1 blockade. Tumor eradication by CD25-ADC was CD8+ T cell-dependent and it induced protective immunity. Importantly, while CD25-ADC mediated a significant and sustained intratumoral Tregs depletion, accompanied by a concomitant increase in the number of activated and proliferating tumor-infiltrating CD8+ Teffs cells, systemic Tregs depletion was transient, alleviating concerns of potential autoimmune side effects.4

Methods Here we evaluated the anti-tumor activity of CD25-ADC combined with tumor-targeted radiotherapy (RT) or systemic IL-2 in syngeneic solid tumor models.

Results To investigate the combination with radiotherapy, single low doses of CD25-ADC (0.25 or 0.5 mg/kg) were administered intravenously either alone or in combination with image-guided focal radiation in the CT26 syngeneic model. Both doses of CD25-ADC alone induced significant anti-tumor activity compared to the vehicle control. Combination of CD25-ADC, at 0.25 or 0.5 mg/kg, with focal radiotherapy resulted in synergistic anti-tumor activity with 60% and 80% tumor-free survivors (TFS), respectively, at the end of the study. Moreover, re-challenged TFS did not develop new tumors, demonstrating development of tumor-specific protective immunity.The combination of CD25-ADC and systemic IL-2 was investigated in the MC38 syngeneic model. CD25-ADC was administered intravenously either alone (0.25 or 0.5 mg/kg, single dose) or in combination with IL-2 (0.1 or 0.8 mg/kg). Single doses of CD25-ADC elicited significant anti-tumor activity compared to the vehicle control. Combination of CD25-ADC with IL-2 resulted in enhanced anti-tumor activity in both combination groups compared to the respective single agents and the combination was synergistic at the highest IL-2 dose.

Conclusions Together, these new preclinical data show novel promising combination regimens for CD25-ADC and other commonly used anti-cancer treatments and they provide rationale for the investigation of camidanlumab tesirine (ADCT-301), a PBD-based ADC targeting human CD25, in similar clinical combinations settings.


  1. Shang, B., et al., Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep 2015;5: p. 15179.

  2. Liu S, et al., Effects of radiation on T regulatory cells in normal states and cancer: mechanisms and clinical implications. Am J Cancer Res 2015;5(11):p. 3276–85.

  3. Zammarchi, F., et al., A CD25-targeted pyrrolobenzodiazepine dimer-based antibody-drug conjugate shows potent anti-tumor activity in pre-clinical models of solid tumors either alone or in combination with a PD-1 inhibitor. Journal for ImmunoTherapy of Cancer 2018. 6(Supplement 1).

  4. Zammarchi, F., et al., A CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity. Journal for ImmunoTherapy of Cancer 2020. In press.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.